Scarica l'app Stockscreener
32.74
0.80%
0.26
Dopo l'orario di chiusura:
32.74
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
IDYA PE Ratio & Valuation, Is IDYA Overvalued - Intellectia AI
Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo - Yahoo Finance
A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses - Yahoo Finance
IDEAYA Biosciences, Inc. $IDYA Position Decreased by JPMorgan Chase & Co. - MarketBeat
IDEAYA Biosciences Achieves 119.91% Growth, Establishing It as a Multibagger in Biotechnology Sector - Markets Mojo
IDEAYA Biosciences, Inc. (IDYA) stock price, news, quote and history - Yahoo Finance UK
Block Trades: Does IDEAYA Biosciences Inc have a competitive edge2026 Key Highlights & Advanced Technical Analysis Signals - baoquankhu1.vn
Wedbush Reiterates Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
37,595 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Tudor Investment Corp ET AL - MarketBeat
Price-Driven Insight from (IDYA) for Rule-Based Strategy - Stock Traders Daily
IDEAYA begins combination trial of IDE849 and IDE161 cancer drugs By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma – Company Announcemen - Financial Times
IDEAYA Biosciences Opens Weak with 5.14% Gap Down Amid Market Concerns - Markets Mojo
Vanguard disaggregates holdings; affiliates to report separately (IDYA) - stocktitan.net
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Finviz
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and Incyte (INCY) - The Globe and Mail
Assessing IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Weakness - simplywall.st
RBC Capital reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada
RBC Capital reiterates Ideaya Biosciences stock rating on trial delay - Investing.com
Jefferies reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.1%Here's Why - marketbeat.com
IDEAYA Biosciences Sees Unusually High Options Volume (NASDAQ:IDYA) - marketbeat.com
Ideaya Biosciences stock maintained at Outperform by Mizuho on trial timing - Investing.com Canada
Citizens reiterates Ideaya Biosciences stock rating on mUM trial data By Investing.com - Investing.com Canada
Citizens reiterates Ideaya Biosciences stock rating on mUM trial data - Investing.com
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial - Sahm
IDEAYA delays darovasertib trial results to mid-April By Investing.com - Investing.com Canada
IDEAYA delays darovasertib trial results to mid-April - investing.com
Cancer trial readout nears as IDEAYA targets first-half April lock - Stock Titan
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
IDYA Stock Price, Quote & Chart | IDEAYA BIOSCIENCES INC (NASDAQ:IDYA) - ChartMill
(IDYA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Barclays Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
IDEAYA Biosciences (IDYA) Gets a Buy from Mizuho Securities - The Globe and Mail
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs – Company Announcement - Financial Times
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs - Barchart
IDEAYA Biosciences, Inc. $IDYA Shares Purchased by Cinctive Capital Management LP - MarketBeat
Iron Triangle Partners LP Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
A Look At IDEAYA Biosciences (IDYA) Valuation After IDE892 Trial Enrollment And Pipeline Refocus - simplywall.st
IDEAYA Biosciences, Inc. $IDYA Position Increased by Baker BROS. Advisors LP - MarketBeat
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
42,283 Shares in IDEAYA Biosciences, Inc. $IDYA Bought by WINTON GROUP Ltd - MarketBeat
Truist reiterates Ideaya Biosciences stock rating on MTAP program By Investing.com - Investing.com Canada
IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating - TipRanks
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update - Finviz
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial - GuruFocus
Ideaya Biosciences announces first-patient-in for phase 1 trial of IDE892 - marketscreener.com
Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892 - TradingView
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update – Company Announcement - Financial Times
IDEAYA Biosciences announces the latest development timeline for its Cdkn2a project - Bitget
IDYA SEC FilingsIdeaya Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
(IDYA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Goldman Sachs Maintains IDEAYA Biosciences (IDYA) Neutral Recommendation - MSN
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC - finance.yahoo.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):